Ionis Reports Second Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. META
4. SPY
5. CART
6. GMAB
7. FFAI
8. INTC
9. TSLA
10. FFR

Go back to Ionis Reports Second Quarter 2019 Financial Results

Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 26c, Revenues Beat

August 7, 2019 7:24 AM EDT

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.01), $0.26 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $164 million versus the consensus estimate of $145.57 million.

"We enter the second half of 2019 in a position of substantial financial strength driven by revenue growth of more than 75 percent. SPINRAZA's blockbuster performance, with over $1 billion in net sales in the first half, contributed significantly to our strong financial results. There are approximately 8,400 patients on SPINRAZA, an increase of approximately 12 percent compared to last quarter. Product sales from TEGSEDI\'s second full... More